Key Takeaways Phibro's Animal Health unit grew 42% with a standout 68% rise in MFAs and other product sales in fiscal Q3. Phibro saw 40% of fiscal Q3 revenues from international markets like Latin America, India and Southeast Asia. PAHC's Mineral Nutrition and Performance Products units posted double-digit sales growth recovery.Phibro Animal Health Corporation’s (PAHC) focus on advancing its Animal Health business is poised to drive growth in the upcoming quarters. The company’s global growth prospects lo ...

Key Takeaways URBN, PAHC and STRT meet momentum criteria with positive trends in price and strong EPS growth. Each stock has outpaced earnings estimates, with STRT posting a 195.8% average surprise over four quarters. URBN and PAHC hold Momentum Score of A and B, respectively, signaling continued price strength.Wall Street may encounter volatility as trade tensions between the United States and China reignite. The United States blamed China for breaching a temporary trade deal, while Beijing accused Washi ...

Summary of Fibro Animal Health Conference Call Company Overview - **Company Name**: Fibro Animal Health - **Ticker Symbol**: PAHC - **Founded**: 1946 - **Employees**: Approximately 2,300 - **Manufacturing Plants**: 6 to 18 worldwide - **Product Registrations**: About 22,000 - **Global Reach**: Customers in approximately 100 countries - **Fiscal Year End**: June 30 Industry Context - **Sector**: Food Animal Health - **Market Demand**: The global population is expected to reach 10 billion in the next couple of decades, necessitating a 70% increase in animal-based protein production [4][4] - **Sustainability Focus**: The company aims to produce more with fewer natural resources, emphasizing animal health and welfare [4][4] Financial Performance - **Fiscal Year 2024 Revenue**: Achieved $1 billion before the acquisition of Zoetis' medicated feed additive business [6][6] - **Pro Forma Revenue Post-Acquisition**: Expected to reach approximately $1.4 billion [15][15] - **EBITDA Margins**: Targeted low 20% margins; currently achieving mid to high 20% margins on the acquired business [15][15] - **Sales Growth**: Legacy business sales up 8% year-over-year; EBITDA up 26% [21][21] - **Guidance for Fiscal Year**: Net sales projected between $1.26 billion and $1.29 billion, with EBITDA between $177 million and $183 million [29][29] Acquisition Insights - **Acquisition of Zoetis MFA Business**: - Completed integration process deemed successful [14][14] - Acquisition was strategic, enhancing revenue diversification and market presence [11][11] - Introduced new geographies and balanced product offerings across species [16][16] - Sales from Zoetis products in the first five months totaled $113 million, with a full-year estimate of $350 million [30][30] Product Portfolio - **Core Product Categories**: - **Medicated Feed Additives**: Includes antimicrobials, antioxidants, and anthelmintics [22][22] - **Nutritional Specialties**: Non-medicated products aimed at maintaining animal health [25][25] - **Vaccines**: Primarily poultry vaccines, including custom autogenous vaccines [27][28] Market Trends and Opportunities - **Geographic Expansion**: Increased focus on Europe, which previously represented only 8% of the Zoetis business [18][18] - **Species Focus**: Strengthened presence in beef and swine markets, particularly in the U.S. [42][42] - **Sustainability Market**: Recognized as a growing opportunity, particularly in dairy, with potential for technology solutions to address environmental concerns [59][60] Challenges and Future Outlook - **Headwinds**: Anticipated tariffs could impact EBITDA by $5 million to $10 million [34][34] - **Transformation Initiative**: "Fiber Forward" aims to enhance income growth through cost and sales strategies [34][34] - **Long-term Growth**: Positive outlook for continued growth across all business lines, with a focus on vaccines, nutritional specialties, and medicated feed additives [32][32] Conclusion Fibro Animal Health is positioned for significant growth following its acquisition of Zoetis' MFA business, with a strong focus on sustainability and expanding its market presence across various species and geographies. The company is optimistic about its financial performance and future opportunities in the animal health sector.

Company Overview - Phibro Animal Health (PAHC) currently has a Momentum Style Score of B, indicating a positive momentum outlook [2] - The company is rated 2 (Buy) by the Zacks Rank, which has a strong track record of outperforming the market [3] Momentum Indicators - PAHC shares have increased by 6.81% over the past week, outperforming the Zacks Medical - Products industry, which rose by 2.46% during the same period [5] - Over the last month, PAHC's stock price has changed by 41.37%, significantly higher than the industry's 3.6% performance [5] - In the last quarter, PAHC shares increased by 9%, and over the past year, they gained 31.14%, while the S&P 500 saw movements of -2.63% and 13.25%, respectively [6] Trading Volume - The average 20-day trading volume for PAHC is 258,588 shares, which serves as a baseline for price-to-volume analysis [7] Earnings Outlook - In the past two months, four earnings estimates for PAHC have been revised upwards, with no downward revisions, leading to an increase in the consensus estimate from $1.94 to $2.01 [9] - For the next fiscal year, four estimates have also moved upwards without any downward revisions [9] Conclusion - Considering the positive momentum indicators and earnings outlook, PAHC is positioned as a promising investment opportunity with a Momentum Score of B [11]

Phibro Animal Health Corporation Financial Results Fiscal Year 2025 Third Quarter Ended March 31, 2025 Webcast and Conference Call May 8, 2025 Webcast and Conference Call May 8, 2025 U.S. toll-free +1.888.330.2022 Cautionary Statement Regarding Forward-Looking Statements This communication contains forward-looking statements that are subject to risks and uncertainties, including with respect to any future debt and leverage levels. All statements other than statements of historical or current fact included i ...

Financial Data and Key Metrics Changes - Total sales increased by 32% year over year, reaching $347.8 million for the quarter ended March 31, 2025 [12] - Adjusted EBITDA rose by 85%, reflecting strong operational performance [7][12] - Adjusted diluted EPS more than doubled compared to the previous year [7] Business Segment Data and Key Metrics Changes - The Animal Health segment led with a 42% revenue growth, totaling $258.4 million [12][14] - Nutritional Specialties achieved 8% revenue growth, while Performance Products saw a significant increase of 28% [9][12] - Newly integrated MSA and other products within Animal Health experienced a 68% increase in sales [8][14] Market Data and Key Metrics Changes - The company anticipates some pressure on certain inputs and markets in the range of $5 million to $10 million due to tariffs in fiscal year 2026 [10] - The overall performance in international markets was stable, with limited impact from foreign exchange fluctuations [44] Company Strategy and Development Direction - The "Fiber Forward" strategy focuses on disciplined operations and continuous improvement, contributing to current performance [9][10] - The company is making targeted investments in procurement and supply chain resilience to manage potential disruptions [10][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating external challenges, including tariffs, without significant impact on financial results for the remainder of fiscal year 2025 [10][22] - The updated guidance reflects solid execution and continued momentum, with net sales expected between $1.26 billion and $1.29 billion [11][20] Other Important Information - The company generated $49 million of positive free cash flow for the twelve months ended March 31, 2025 [17] - Cash and cash equivalents were $70 million at the end of the quarter [17] Q&A Session Summary Question: Can you elaborate on the company's exposure to upcoming pharma tariffs? - Management indicated that most manufacturing is done in the U.S., with some inputs sourced from other markets, and they have implemented measures to mitigate tariff impacts [25][27] Question: What drove the slower growth in the Medicaid fee added business? - The decline was attributed to the timing of orders from larger customers, with overall year-to-date growth remaining positive [28][29] Question: What factors are driving the increase in guidance for EBITDA and EPS? - The increase is driven by a favorable mix, strong vaccine performance, and contributions from the Zoetis MFA portfolio [32][35] Question: Can you provide more details on the specific products affected by tariffs? - The impact is primarily from inputs subject to general tariffs rather than specific products from China [38] Question: Is the company lobbying for exceptions from potential pharma tariffs? - Management confirmed involvement in lobbying efforts for exceptions, emphasizing the importance of these products in food pricing [42] Question: What was the FX impact for the quarter? - Limited impact was noted, with efforts to transact in U.S. dollars to minimize foreign exchange effects [44]

Financial Performance and Key Metrics - Total sales increased by 32% year over year, reaching $347.8 million, with adjusted EBITDA rising by 85% and adjusted diluted EPS more than doubling [6][11][10] - GAAP net income and diluted EPS saw significant increases, driven by the integration of the new MFA business and improved gross margins [11][12] - Adjusted EBITDA for the third quarter increased by $25.2 million, reflecting strong sales growth and improved operating leverage [12][10] Business Segment Performance - The Animal Health segment led with a 42% revenue growth, contributing $258.4 million in net sales [12][11] - Newly integrated MSA and other products within Animal Health saw a 68% increase in sales, while legacy MSA and other products declined by 3% [7][13] - Nutritional Specialties maintained an 8% revenue growth, while Performance Products posted a remarkable 28% increase [7][15] Market Data and Key Indicators - The company anticipates some pressure on certain inputs and markets in the range of $5 million to $10 million due to tariffs in fiscal year 2026, but believes it is well-positioned to manage these impacts [9][21] - The overall performance reflects strong execution and operational excellence, which are central themes of the company's Fiber Forward strategy [7][8] Company Strategy and Industry Competition - The Fiber Forward strategy emphasizes disciplined operations and continuous improvement, contributing to the company's performance and ability to navigate external challenges [8][9] - The company is focused on unlocking additional areas of revenue growth and cost savings through various initiatives, including potential price increases and expanded product offerings [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering strong income growth in fiscal year 2026, driven by continued strong performance in the legacy business and a full year of revenue contribution from the Zoetis MFA portfolio [21][10] - The company does not expect any material impact from the evolving tariff environment on its financial results for the remainder of fiscal year 2025 [9][21] Other Important Information - The company generated $49 million of positive free cash flow for the twelve months ended March 31, 2025, with cash and cash equivalents totaling $70 million at the end of the quarter [16][17] - The gross leverage ratio was 3.0x, and the net leverage ratio was 2.7x at the end of the third quarter [17] Q&A Session Summary Question: Can you elaborate on the company's exposure to upcoming pharma tariffs and potential mitigation strategies? - Management indicated that most manufacturing is done in the U.S., with some inputs sourced from other markets. They have built inventory, switched suppliers, and announced price increases to mitigate tariff impacts [23][26] Question: What drove the slower growth in the Medicaid fee added business? - The slower growth was attributed to the timing of orders from larger customers and a difficult comparative quarter from the previous year, but overall demand remains strong [27][28] Question: What factors are driving the increase in guidance for EBITDA and EPS? - The increase is driven by a favorable mix, strong performance in the vaccine portfolio, and improved margins from the Zoetis MFA portfolio [32][33] Question: Can you provide more details on the specific products affected by tariffs? - The impact is primarily from inputs subject to general tariffs rather than specific products from China, with ongoing efforts to manage costs and supplier negotiations [36][37] Question: Is the company lobbying for exceptions from potential pharma tariffs? - Management confirmed involvement in lobbying efforts for exceptions, emphasizing the importance of these products in the food supply chain [40][41]

Core Viewpoint - Phibro Animal Health (PAHC) reported strong adjusted earnings per share (EPS) for Q3 fiscal 2025, significantly exceeding the previous year's performance, although revenue slightly missed expectations [1][2][10]. Financial Performance - Adjusted EPS for Q3 was 63 cents, up from 31 cents year-over-year, beating the Zacks Consensus Estimate by 21.1% [1] - GAAP EPS was 51 cents compared to 21 cents in the prior-year period [1] - Net sales reached $347.8 million, a 23.8% increase from the previous year, but fell short of the Zacks Consensus Estimate by 0.7% [2] Segment Performance - Animal Health segment net sales increased by 42% to $258.4 million, although it was below the projected $262.2 million [3] - Medicated feed additives (MFAs) and other products saw a 68% year-over-year growth, contributing $77 million from the Zoetis MFA portfolio acquisition [4] - Mineral Nutrition segment sales rose 4% to $66.8 million, while Performance Products segment sales increased by 28% to $22.7 million, surpassing projections [5] Margin Analysis - Gross profit for Q3 increased by 31.3% to $104.5 million, with a gross margin of 30.1%, down 20 basis points year-over-year [6] - Operating profit rose 67.8% to $33.4 million, with an operating margin expansion of 204 basis points to 9.6% [6] Cash Position - At the end of Q3, the company had cash and short-term investments of $70.4 million, up from $67.1 million at the end of Q2 [7] - Cumulative net cash from operating activities was $58.9 million, slightly down from $59.2 million year-over-year [7] Guidance Update - For fiscal 2025, PAHC expects net sales between $1.26 billion and $1.29 billion, indicating a 25% growth, with adjusted EPS projected between $1.96 and $2.09 [9] - The revised guidance reflects a 70% improvement compared to earlier projections [9] Overall Assessment - The company achieved an earnings beat but a revenue miss in Q3, with strong growth driven by the Animal Health segment and successful integration of the Zoetis MFA business [10] - The outlook for fiscal 2025 remains positive despite some margin contraction and challenges in product sales timing [10][11]

Core Insights - Phibro Animal Health (PAHC) reported a revenue of $347.8 million for the quarter ended March 2025, marking a year-over-year increase of 32.1% and an EPS of $0.63 compared to $0.31 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $350.54 million by 0.78%, while the EPS exceeded the consensus estimate of $0.52 by 21.15% [1] Financial Performance - The company’s net sales by region showed varied performance: - United States: $209.94 million, a 31.8% increase year-over-year, but below the estimated $221.68 million [4] - Asia Pacific: $28.22 million, a significant 65.2% increase year-over-year, exceeding the estimate of $23.44 million [4] - Europe, Middle East and Africa: $38.91 million, a 17.3% increase year-over-year, below the estimate of $48.03 million [4] - Latin America and Canada: $70.75 million, a 31.9% increase year-over-year, surpassing the estimate of $55.39 million [4] Segment Performance - Animal Health segment reported net sales of $258.40 million, a 42.5% increase year-over-year, but below the estimate of $265.65 million [4] - Mineral Nutrition segment reported net sales of $66.80 million, a 4% increase year-over-year, slightly below the estimate of $66.88 million [4] - Animal Health Vaccines reported net sales of $33.40 million, a 1.5% increase year-over-year, below the estimate of $38.78 million [4] - Animal Health MFAs and other reported net sales of $181.60 million, a substantial 67.8% increase year-over-year, exceeding the estimate of $155.57 million [4] - Performance Products reported net sales of $22.70 million, a 28.5% increase year-over-year, surpassing the estimate of $18.01 million [4] EBITDA Performance - Adjusted EBITDA for the Animal Health segment was $63.10 million, above the average estimate of $60.59 million [4] - Adjusted EBITDA for the Corporate segment was -$17.30 million, better than the estimated -$19.57 million [4] Stock Performance - Phibro's shares have returned +6.5% over the past month, compared to the Zacks S&P 500 composite's +10.6% change, with a current Zacks Rank of 3 (Hold) indicating potential performance in line with the broader market [3]

Core Viewpoint - Phibro Animal Health (PAHC) reported quarterly earnings of $0.63 per share, exceeding the Zacks Consensus Estimate of $0.52 per share, and showing significant growth from $0.31 per share a year ago [1][2]. Financial Performance - The earnings surprise for the quarter was 21.15%, with the company previously expected to earn $0.42 per share but actually earning $0.54, resulting in a surprise of 28.57% [2]. - Phibro's revenues for the quarter were $347.8 million, slightly missing the Zacks Consensus Estimate by 0.78%, compared to $263.2 million in the same quarter last year [3]. - Over the last four quarters, the company has surpassed consensus EPS estimates four times and topped revenue estimates twice [2][3]. Stock Performance - Phibro shares have declined approximately 9.3% since the beginning of the year, while the S&P 500 has decreased by 4.7% [4]. - The current Zacks Rank for Phibro is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [7]. Future Outlook - The consensus EPS estimate for the upcoming quarter is $0.53, with expected revenues of $355.98 million, and for the current fiscal year, the estimate is $1.94 on $1.28 billion in revenues [8]. - The outlook for the Medical - Products industry, to which Phibro belongs, is currently in the bottom 28% of over 250 Zacks industries, which may impact stock performance [9].